Thr105
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr105  -  TNRC15 (human)

Site Information
sAAVLRLtGrGGGGt   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 34349107

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 )
Disease tissue studied:
brain cancer ( 2 ) , glioblastoma ( 2 ) , glioma ( 2 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 1 ) , acute megakaryoblastic leukemia (M7) ( 1 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 1 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 1 ) , acute myeloblastic leukemia, without maturation (M1) ( 1 ) , B cell lymphoma ( 1 ) , non-Hodgkin's lymphoma ( 1 ) , multiple myeloma ( 1 )
Relevant cell line - cell type - tissue:

References 

1

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

2

Stokes M (2007) CST Curation Set: 2262; Year: 2007; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info